“EMA has started evaluating an application for a conditional marketing authorization for the oral antiviral medicine Paxlovid,” the EU regulator said in a statement.
The statement said that the regulator could deliver its assessment within weeks since it had already carried out a preliminary review based on laboratory, animal, and clinical studies.
Following EMA’s recommendation, the European Commission would officially give the marketing authorization.
The medicine reduces the ability of the virus to multiply in the body.
By treating adults and adolescents with mild-to-moderate symptoms of COVID-19, the drug can lower the risk of developing severe illness and hospitalization.